A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Development of Generalized Disease at 2 Years in Patients with Ocular Myasthenia Gravis
Arch Neurol 60:243-248, Kupersmith,M.J.,et al, 2003
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Total Body Irradiation for Myasthenia Gravis:A Long-Term Follow-up
Neurol 43:2215-2221, Durelli,L.,et al, 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Memory Dysfunction in Myasthenia Gravis:Evidence for Central Cholinergic Effects
Neurol 38:1173-1177, Tucker,D.M.,et al, 1988
Humoral Immunity in Myasthenia Gravis:Effect of Steroids & Thymectomy
Neurol 30:554-557, Tindall,R.S.A., 1980
Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978
Content of Acetylch Receptor & Antib Bound to Receptor in Myasth Gravis, Experi Autoimm Myasth Gravis, & Syndrome
Neurol 28:130, Lindstrom,J.M., 1978
Plasmapheresis & Immunosuppressive Drug Therapy in Myasthenia Gravis
NEJM 297:1134, Dau,P.C.,et al, 1977
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
A Randomized Controlled Trial of Methotrexate for Patients with Generalized Myasthenia Gravis
Neurol 87:57-64, Pasnoor, M.,et al, 2016
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis
JAMA Neurol 72:1170-1174, Peeler, C.E.,et al, 2015
Overlooked non-motor Symptoms in Myasthenia Gravis
JNNP 84:989-994, Suzuki, S.,et al, 2013
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
A Trial of Mycophenolate Mofetil With Prednisone as Initial Immunotherapy of Myasthenia Gravis
Neurol 71:394-399,390, The Muscle Study Group, 2008
An International, Phase III, Randomized Trial of Mycophenolate Mofetil in Myasthenia Gravis
Neurol 71:400-406, 390, Sanders,D.B.,et al., 2008
Treatment of Ocular Symptoms in Myasthenia Gravis
Neurol 71:1335-1341, Bhanushali,M.J.,et al, 2008
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Mysterious Falls and a Nasal Voice
Lancet 370:712, Bhandari,A. &Adenwalla,F., 2007
Immunosuppressive or Surgical Treatment for Ocular Myasthenia Gravis
Arch Neurol 64:1792-1794,1794, Chavis,P.S.,et al, 2007
Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007
Extrathymic Tumors in Patients With Myasthenia Gravis, A 35-Year Retrospective Study
The Neurologist 12:53-55, Wakata,N.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Dysphagia as the Sole Manisfestation of Myasthenia Gravis
JNNP 76:1297-1300, Llabrs,M.,et al, 2005